Entera Bio appoints Riccardo Paolo Camisasca as CMO ahead of EB613 Phase 3

Entera Bio Ltd.

Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer effective Aug 18, 2026.
He brings 30+ years experience; most recently Global Head of R&D at Sumitomo Pharma Switzerland.
Appointment strengthens clinical team ahead of planned EB613 Phase 3 initiation for osteoporosis.
Previously led R&D integration across Urovant, Enzyvant, Altavant, and Myovant at Sumitomo.
CEO Miranda Toledano cites his rare combination of developing drugs across global R&D organizations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.